Cargando…

A nomogram based on (18)F-fluorodeoxyglucose PET/CT and clinical features to predict epidermal growth factor receptor mutation status in patients with lung adenocarcinoma

BACKGROUND: Identifying epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma (LADC) is vital for treatment decision-making. This study aimed to establish a convenient and noninvasive nomogram prediction model based on (18)F-fluorodeoxyglucose positron emission tomography/computed...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yue, Zhu, Hui, Chen, Congxia, Li, Xu, Liu, Fugeng, Yao, Zhiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622444/
https://www.ncbi.nlm.nih.gov/pubmed/36330175
http://dx.doi.org/10.21037/qims-22-248
_version_ 1784821769639559168
author Guo, Yue
Zhu, Hui
Chen, Congxia
Li, Xu
Liu, Fugeng
Yao, Zhiming
author_facet Guo, Yue
Zhu, Hui
Chen, Congxia
Li, Xu
Liu, Fugeng
Yao, Zhiming
author_sort Guo, Yue
collection PubMed
description BACKGROUND: Identifying epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma (LADC) is vital for treatment decision-making. This study aimed to establish a convenient and noninvasive nomogram prediction model based on (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) imaging and clinical features to predict EGFR mutation status in patients with LADC. METHODS: A total of 274 patients (male 130, female 144, median age 65 years) were enrolled in this retrospective study. Imaging data from (18)F-FDG PET/CT and clinical information were analyzed, with the Mann-Whitney U test, Student’s t-test, and chi-square test used to compare categorical or continuous covariates as appropriate. Logistic regression analyses were performed to identify independent variables associated with EGFR mutation status, from which the nomogram prediction model was constructed. Leave-one-out cross-validation was performed, and the discrimination ability and calibration of the nomogram were assessed by calculating the area under the curve of the receiver operating characteristic curve and the calibration curve. The clinical net benefit of the nomogram was evaluated. RESULTS: Of the 274 patients, 143 (52.2%) had EGFR mutations. Female sex [odds ratios (OR): 2.64, 95% confidence interval (CI): 1.29–5.45, P=0.008], non-smoking status (OR: 2.78, 95% CI: 1.30–5.88, P=0.008), mean standardized uptake value ≤9.23 (OR: 2.44, 95% CI: 1.35–4.55, P=0.004), metabolic tumor volume ≤17.72 cm(3) (OR: 5.00, 95% CI: 2.38–12.50, P<0.001) and the presence of pleural retraction (OR: 1.88, 95% CI: 1.05–3.40, P=0.034) were independent predictors for EGFR mutations in LADCs. The nomogram based on these risk factors showed good predictive efficacy, with an area under the curve of 0.805 (95% CI: 0.753–0.857), a sensitivity of 90.2%, a specificity of 59.5% and an accuracy of 73.0%. CONCLUSIONS: The nomogram prediction model incorporating sex, smoking status, mean standardized uptake value, metabolic tumor volume, and the presence of pleural retraction could effectively discriminate EGFR-mutant from wild-type LADCs.
format Online
Article
Text
id pubmed-9622444
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-96224442022-11-02 A nomogram based on (18)F-fluorodeoxyglucose PET/CT and clinical features to predict epidermal growth factor receptor mutation status in patients with lung adenocarcinoma Guo, Yue Zhu, Hui Chen, Congxia Li, Xu Liu, Fugeng Yao, Zhiming Quant Imaging Med Surg Original Article BACKGROUND: Identifying epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma (LADC) is vital for treatment decision-making. This study aimed to establish a convenient and noninvasive nomogram prediction model based on (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) imaging and clinical features to predict EGFR mutation status in patients with LADC. METHODS: A total of 274 patients (male 130, female 144, median age 65 years) were enrolled in this retrospective study. Imaging data from (18)F-FDG PET/CT and clinical information were analyzed, with the Mann-Whitney U test, Student’s t-test, and chi-square test used to compare categorical or continuous covariates as appropriate. Logistic regression analyses were performed to identify independent variables associated with EGFR mutation status, from which the nomogram prediction model was constructed. Leave-one-out cross-validation was performed, and the discrimination ability and calibration of the nomogram were assessed by calculating the area under the curve of the receiver operating characteristic curve and the calibration curve. The clinical net benefit of the nomogram was evaluated. RESULTS: Of the 274 patients, 143 (52.2%) had EGFR mutations. Female sex [odds ratios (OR): 2.64, 95% confidence interval (CI): 1.29–5.45, P=0.008], non-smoking status (OR: 2.78, 95% CI: 1.30–5.88, P=0.008), mean standardized uptake value ≤9.23 (OR: 2.44, 95% CI: 1.35–4.55, P=0.004), metabolic tumor volume ≤17.72 cm(3) (OR: 5.00, 95% CI: 2.38–12.50, P<0.001) and the presence of pleural retraction (OR: 1.88, 95% CI: 1.05–3.40, P=0.034) were independent predictors for EGFR mutations in LADCs. The nomogram based on these risk factors showed good predictive efficacy, with an area under the curve of 0.805 (95% CI: 0.753–0.857), a sensitivity of 90.2%, a specificity of 59.5% and an accuracy of 73.0%. CONCLUSIONS: The nomogram prediction model incorporating sex, smoking status, mean standardized uptake value, metabolic tumor volume, and the presence of pleural retraction could effectively discriminate EGFR-mutant from wild-type LADCs. AME Publishing Company 2022-11 /pmc/articles/PMC9622444/ /pubmed/36330175 http://dx.doi.org/10.21037/qims-22-248 Text en 2022 Quantitative Imaging in Medicine and Surgery. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Guo, Yue
Zhu, Hui
Chen, Congxia
Li, Xu
Liu, Fugeng
Yao, Zhiming
A nomogram based on (18)F-fluorodeoxyglucose PET/CT and clinical features to predict epidermal growth factor receptor mutation status in patients with lung adenocarcinoma
title A nomogram based on (18)F-fluorodeoxyglucose PET/CT and clinical features to predict epidermal growth factor receptor mutation status in patients with lung adenocarcinoma
title_full A nomogram based on (18)F-fluorodeoxyglucose PET/CT and clinical features to predict epidermal growth factor receptor mutation status in patients with lung adenocarcinoma
title_fullStr A nomogram based on (18)F-fluorodeoxyglucose PET/CT and clinical features to predict epidermal growth factor receptor mutation status in patients with lung adenocarcinoma
title_full_unstemmed A nomogram based on (18)F-fluorodeoxyglucose PET/CT and clinical features to predict epidermal growth factor receptor mutation status in patients with lung adenocarcinoma
title_short A nomogram based on (18)F-fluorodeoxyglucose PET/CT and clinical features to predict epidermal growth factor receptor mutation status in patients with lung adenocarcinoma
title_sort nomogram based on (18)f-fluorodeoxyglucose pet/ct and clinical features to predict epidermal growth factor receptor mutation status in patients with lung adenocarcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622444/
https://www.ncbi.nlm.nih.gov/pubmed/36330175
http://dx.doi.org/10.21037/qims-22-248
work_keys_str_mv AT guoyue anomogrambasedon18ffluorodeoxyglucosepetctandclinicalfeaturestopredictepidermalgrowthfactorreceptormutationstatusinpatientswithlungadenocarcinoma
AT zhuhui anomogrambasedon18ffluorodeoxyglucosepetctandclinicalfeaturestopredictepidermalgrowthfactorreceptormutationstatusinpatientswithlungadenocarcinoma
AT chencongxia anomogrambasedon18ffluorodeoxyglucosepetctandclinicalfeaturestopredictepidermalgrowthfactorreceptormutationstatusinpatientswithlungadenocarcinoma
AT lixu anomogrambasedon18ffluorodeoxyglucosepetctandclinicalfeaturestopredictepidermalgrowthfactorreceptormutationstatusinpatientswithlungadenocarcinoma
AT liufugeng anomogrambasedon18ffluorodeoxyglucosepetctandclinicalfeaturestopredictepidermalgrowthfactorreceptormutationstatusinpatientswithlungadenocarcinoma
AT yaozhiming anomogrambasedon18ffluorodeoxyglucosepetctandclinicalfeaturestopredictepidermalgrowthfactorreceptormutationstatusinpatientswithlungadenocarcinoma
AT guoyue nomogrambasedon18ffluorodeoxyglucosepetctandclinicalfeaturestopredictepidermalgrowthfactorreceptormutationstatusinpatientswithlungadenocarcinoma
AT zhuhui nomogrambasedon18ffluorodeoxyglucosepetctandclinicalfeaturestopredictepidermalgrowthfactorreceptormutationstatusinpatientswithlungadenocarcinoma
AT chencongxia nomogrambasedon18ffluorodeoxyglucosepetctandclinicalfeaturestopredictepidermalgrowthfactorreceptormutationstatusinpatientswithlungadenocarcinoma
AT lixu nomogrambasedon18ffluorodeoxyglucosepetctandclinicalfeaturestopredictepidermalgrowthfactorreceptormutationstatusinpatientswithlungadenocarcinoma
AT liufugeng nomogrambasedon18ffluorodeoxyglucosepetctandclinicalfeaturestopredictepidermalgrowthfactorreceptormutationstatusinpatientswithlungadenocarcinoma
AT yaozhiming nomogrambasedon18ffluorodeoxyglucosepetctandclinicalfeaturestopredictepidermalgrowthfactorreceptormutationstatusinpatientswithlungadenocarcinoma